• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

马达加斯加地区曲菌病患者应用伊曲康唑治疗的反应。

Treatment responses in patients with chromoblastomycosis to itraconazole in Madagascar.

机构信息

Department of Dermatology, Faculty of Medicine, University of Antananarivo, Antananarivo 101, Madagascar.

Centre d'Infectiologie Charles Mérieux, University of Antananarivo, Antananarivo 101, Madagascar.

出版信息

Med Mycol. 2022 Nov 12;60(11). doi: 10.1093/mmy/myac086.

DOI:10.1093/mmy/myac086
PMID:36288247
Abstract

INTRODUCTION

Chromoblastomycosis (CBM) is a chronic fungal infection of the skin and subcutaneous tissue caused by several pigmented fungi. It is frequently found in tropical and subtropical areas like Madagascar. This study primarily discusses the effects of antifungal therapy while also describing the epidemiological, clinical, and pathological features of CBM in our patients.

METHODS

From March 2013 to January 2019, a descriptive prospective study on CBM patients was undertaken. The study included patients with CBM who had received antifungal treatment for at least 3 months. Itraconazole 200 mg was given to patients every day for ˃3 months. Results were assessed at the 6th and 12th months and classified as major responses, minor responses to treatment, or failure.

RESULTS

A total of 29 cases of CBM were included. The mean age of patients was 42.02 years. They primarily worked in rural areas. Infected men were more prevalent. At the end of the 12th month of itraconazole therapy, 3 patients presented major responses, 14 patients had minor responses to treatment, and 12 had been lost to follow-up. The clinical response of CBM to treatment was correlated to the severity and the long course of CBM. When compared with CBM caused by Cladophialophora, CBM caused by Fonsecaea showed a greater clinical response.

CONCLUSION

These findings demonstrated that CBM lesions are recalcitrant and difficult to treat.

摘要

引言

着色芽生菌病(CBM)是一种由几种色素真菌引起的皮肤和皮下组织慢性真菌感染。它在马达加斯加等热带和亚热带地区很常见。本研究主要讨论抗真菌治疗的效果,同时描述我们患者的 CBM 的流行病学、临床和病理特征。

方法

从 2013 年 3 月至 2019 年 1 月,对 CBM 患者进行了一项描述性前瞻性研究。该研究包括接受至少 3 个月抗真菌治疗的 CBM 患者。每天给予患者伊曲康唑 200mg,持续时间大于 3 个月。在第 6 个月和第 12 个月评估结果,并将其分类为主要反应、治疗的次要反应或失败。

结果

共纳入 29 例 CBM 患者。患者的平均年龄为 42.02 岁。他们主要在农村地区工作。感染男性更为常见。在伊曲康唑治疗的第 12 个月结束时,3 名患者出现主要反应,14 名患者治疗有轻微反应,12 名患者失访。CBM 对治疗的临床反应与 CBM 的严重程度和长期病程有关。与由 Cladophialophora 引起的 CBM 相比,由 Fonsecaea 引起的 CBM 表现出更大的临床反应。

结论

这些发现表明 CBM 病变具有顽固性和难治性。

相似文献

1
Treatment responses in patients with chromoblastomycosis to itraconazole in Madagascar.马达加斯加地区曲菌病患者应用伊曲康唑治疗的反应。
Med Mycol. 2022 Nov 12;60(11). doi: 10.1093/mmy/myac086.
2
[Management of chromoblastomycosis, a challenge for limited-resource countries such as Madagascar].[着色芽生菌病的管理:马达加斯加等资源有限国家面临的挑战]
Ann Dermatol Venereol. 2020 May;147(5):377-382. doi: 10.1016/j.annder.2020.01.018. Epub 2020 Mar 24.
3
Clinical aspects of previously treated chromoblastomycosis: A case series from Madagascar.既往治疗过的着色芽生菌病的临床方面:来自马达加斯加的病例系列。
Int J Infect Dis. 2020 Dec;101:228-232. doi: 10.1016/j.ijid.2020.09.1479. Epub 2020 Oct 2.
4
Endemic Chromoblastomycosis Caused Predominantly by Fonsecaea nubica, Madagascar.马达加斯加主要由拟青霉引起的地方性着色芽生菌病。
Emerg Infect Dis. 2020 Jun;26(6):1201-1211. doi: 10.3201/eid2606.191498.
5
Epidemiological and clinical aspects of sporotrichosis in patients seen at a reference hospital in Madagascar.马达加斯加一家参考医院就诊的孢子丝菌病患者的流行病学和临床方面。
PLoS Negl Trop Dis. 2023 Jul 26;17(7):e0011478. doi: 10.1371/journal.pntd.0011478. eCollection 2023 Jul.
6
Effect of Melanin Biosynthesis Inhibition on the Antifungal Susceptibility of Chromoblastomycosis Agents.黑色素生物合成抑制对暗色丝孢霉病病原体抗真菌敏感性的影响。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0054621. doi: 10.1128/AAC.00546-21.
7
Successful management of chromoblastomycosis utilizing conventional antifungal agents and imiquimod therapy.成功运用常规抗真菌药物和咪喹莫特疗法治疗着色芽生菌病。
Ann Clin Microbiol Antimicrob. 2024 Jun 20;23(1):57. doi: 10.1186/s12941-024-00718-y.
8
Chromoblastomycosis in the Amazon region, Brazil, caused by Fonsecaea pedrosoi, Fonsecaea nubica, and Rhinocladiella similis: Clinicopathology, susceptibility, and molecular identification.巴西亚马逊地区由裴氏瓶霉、暗瓶霉和相似枝孢霉引起的着色芽生菌病:临床病理学、易感性及分子鉴定
Med Mycol. 2020 Feb 1;58(2):172-180. doi: 10.1093/mmy/myz034.
9
5-aminolevulinic acid-based photodynamic therapy associated with Itraconazole successfully treated a case of chromoblastomycosis.5-氨基酮戊酸光动力疗法联合伊曲康唑成功治疗一例着色芽生菌病。
Photodiagnosis Photodyn Ther. 2020 Mar;29:101589. doi: 10.1016/j.pdpdt.2019.101589. Epub 2019 Nov 2.
10
Cutaneous localized annular chromoblastomycosis.皮肤局限性环状着色芽生菌病
J Cutan Pathol. 2009 Feb;36(2):257-61. doi: 10.1111/j.1600-0560.2008.01025.x. Epub 2008 Aug 24.

引用本文的文献

1
Establishment of epidemiological cutoff values for , the primary etiologic agent of chromoblastomycosis, and eight antifungal medications.建立着色芽生菌病主要病原体及八种抗真菌药物的流行病学截断值。
J Clin Microbiol. 2025 May 14;63(5):e0190324. doi: 10.1128/jcm.01903-24. Epub 2025 Apr 4.
2
A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group.全球暗色丝孢霉病策略和全球暗色丝孢霉病工作组的发展。
PLoS Negl Trop Dis. 2024 Oct 15;18(10):e0012562. doi: 10.1371/journal.pntd.0012562. eCollection 2024 Oct.
3
Chromoblastomycosis in French Guiana: Epidemiology and Practices, 1955-2023.
法属圭亚那的着色芽生菌病:1955年至2023年的流行病学与诊疗情况
J Fungi (Basel). 2024 Feb 22;10(3):168. doi: 10.3390/jof10030168.